Cargando…
First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
BACKGROUND: The [(177)Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist, [(177)Lu]Lu-DOTA-JR11, that demonstrated b...
Autores principales: | Handula, Maryana, Beekman, Savanne, Konijnenberg, Mark, Stuurman, Debra, de Ridder, Corrina, Bruchertseifer, Frank, Morgenstern, Alfred, Denkova, Antonia, de Blois, Erik, Seimbille, Yann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313624/ https://www.ncbi.nlm.nih.gov/pubmed/37389800 http://dx.doi.org/10.1186/s41181-023-00197-0 |
Ejemplares similares
-
Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021) -
Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016) -
Imaging inflammation in atherosclerotic plaques, targeting SST(2) with [(111)In]In-DOTA-JR11
por: Meester, Eric J., et al.
Publicado: (2020) -
Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
por: Rumiantcev, Mikhail, et al.
Publicado: (2023) -
Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)